{"id":"W4403420022","doi":"10.1016/j.jtho.2024.09.075","title":"OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Jewish General Hospital","funders":"Samsung; Genentech; Humanitas Research Hospital; Universitair Ziekenhuis Antwerpen; Jewish General Hospital; Maastricht Universitair Medisch Centrum; Peter MacCallum Cancer Centre; Sungkyunkwan University; University of Manchester; Victoria University; University of Melbourne; Ottawa Hospital Research Institute; Monash University; Università degli Studi di Milano; Hospital de Câncer de Barretos; Seoul National University; Seoul National University Bundang Hospital; McGill University; Yale Cancer Center; Yale University","keywords":"Medicine; Atezolizumab; Term (time); Oncology; KRAS; Internal medicine; Pembrolizumab; Cancer; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004853542,0.0002459056,0.0009158952,0.0002934778,0.0003479517,0.0006696874,0.0003432342,0.0004881884,0.001269473],"category_scores_gemma":[0.0006631776,0.0001603631,0.0008601082,0.0004207362,0.000183777,0.0005930705,0.000260277,0.001050308,0.0002227139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006162232,"about_ca_system_score_gemma":0.0006296677,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001254183,"about_ca_topic_score_gemma":0.004378733,"domain_scores_codex":[0.9997091,0.00004752728,0.0000356927,0.00006491434,0.00005325804,0.00008960658],"domain_scores_gemma":[0.9996159,0.00007078784,0.000104268,0.00002441624,0.00004828582,0.000136302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05280857,0.001493951,0.6571921,0.0005127329,0.001759773,0.002013429,0.0001845346,0.001593403,0.01122215,0.0002650113,0.004708462,0.266246],"study_design_scores_gemma":[0.0036528,0.01991216,0.9491758,0.0002643497,0.003058233,0.00373477,0.0004006831,0.00320944,0.002934395,0.0006733312,0.01291403,0.00007008253],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879878,0.008223213,0.0001607689,0.0004810339,0.0001157885,0.00004372518,0.0006507728,0.00001774106,0.00231927],"genre_scores_gemma":[0.9960651,0.001198295,0.0001330959,0.0003201106,0.00007948746,0.00003398643,0.001279409,0.000003511439,0.0008870839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001269473,"threshold_uncertainty_score":0.004471004,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0199086943894132,"score_gpt":0.3534978687197636,"score_spread":0.3335891743303504,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}